ASAnastasiia Samusieva

Anastasiia Samusieva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anastasiia Samusieva has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Case Report: Synergistic potential of RANKL and ACLY inhibition in a breast cancer patient with acquired resistance to CDK4/6 inhibitors

    by Anastasiia Samusieva, Ielizaveta Gorodetska, Oleg Socha, Yuliia Lytovchenko, Roman Kisielov, Borys Dons`kOi, Daria Kozeretska, Vasyl Lukiyanchuk, Anna Dubrovska, Valeriy Cheshuk, et al.

    Background: The development of acquired resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) represents a major clinical challenge in the management of hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. Overcoming this resistance requires novel therapeutic strategies that target the underlying molecular escape pathways. Case presentation: We report the case of a patient initially diagnosed in 2011 with pT2N0M0, ER+/HER2- invasive ductal carcinoma. Following multimodality treatment, she experienced disease progression with bone metastases after five years, followed by lymph node metastases at the ten-year mark. Subsequent treatment with the CDK4/6i ribociclib in combination with fulvestrant resulted in disease progression approximately one year later, indicating acquired resistance. Due to progressive bone loss, denosumab was initiated for skeletal support, and bempedoic acid was later added for dyslipidemia. Discussion: This case provides a clinical basis for exploring two innovative therapeutic concepts to overcome resistance. First, we discuss the complex role of receptor activator of nuclear factor kappa-B ligand (RANKL) inhibition. Given that leucine-rich repeat-containing G protein-coupled receptor 4 (LGR4) functions as a decoy receptor for RANKL, we hypothesize that a patient’s LGR4 expression status may dictate the efficacy and safety of denosumab, potentially serving as a predictive biomarker to personalize its use. Second, we propose that bempedoic acid, a supportive care medication, may exert a direct anti-neoplastic effect. Its dual mechanism, inhibiting ATP-citrate lyase (ACLY) to disrupt lipid synthesis and activating AMP-activated protein kinase (AMPK) to suppress mammalian target of rapamycin complex 1 (mTORC1) signaling, positions it as a potential agent to counteract the metabolic reprogramming associated with therapeutic resistance. Conclusion: This case report illustrates the sequential development of acquired therapeutic resistance in the long-term management of metastatic breast cancer. Although a single clinical observation cannot establish definitive efficacy, this scenario generates compelling hypotheses for future studies. It highlights the potential need to explore biomarker-driven approaches—such as evaluating LGR4 expression to guide RANKL inhibition—to personalize treatment. Additionally, it raises the possibility that repurposed supportive care medications, such as bempedoic acid, might offer hypothetical anti-neoplastic benefits, warranting broader clinical validation to overcome complex resistance mechanisms.

  • Open Access

    Prevention and Management of Postoperative Seroma in Patients with Breast Cancer: A Narrative Review

    by Anastasiia Samusieva, Vitalii Zaichuk, Prokip Gordiichuk

    Surgical treatment of breast cancer (BC) remains one of the primary modalities for managing this disease, continuously evolving in line with technological and scientific advancements. The extent of...

  • Open Access

    ANGIOSARCOMA ASSOCIATED WITH RADIATION THERAPY IN PATIENTS WITH A HISTORY OF INVASIVE BREAST CARCINOMA. A CASE REPORT AND REVIEW OF THE LITERATURE

    by V. Zaichuk, A. Samusieva, M. Diatel, I. Vashchenko, P. Gordiichuk

    Angiosarcoma of the breast is a rare malignant tumor and accounts for 1% of all soft tissue tumors of the breast. Breast angiosarcoma caused by previous radiation therapy more frequently affects older women with a history of breast cancer. The standard treatment for such patients is radical surgery, but there are still many debatable questions regarding the treatment of these malignant tumors. The purpose of this article is to review the medical literature on angiosarcomas associated with radiotherapy and describe a case as an example.

  • Open Access

    Breast cancer in Ukraine: clinics and diagnostics. Current status and prospects of diagnostics (lecture)

    by A. Samusieva, V. Zaichuk, O. Shcherbina, P. Gordiichuk, О.в. Пономарьова, B. Sorokin, П.о. Король, M. Gordiichuk, П.і. Гордійчук, Б.в. Сорокін, et al.

    The lecture discusses the current state of early Breast Cancer (BC) diagnosis in Ukraine, outlining its epidemiological features, morphological heterogeneity, clinical manifestations, and modern diagnostic methods. BC remains the most common oncological disease among women worldwide, including Ukraine. Each year, over 12,000 new cases are registered in the country, with many patients seeking medical help at advanced stages, which decreases treatment effectiveness and survival rates. The lecture stresses the importance of early diagnosis, achievable through increased physician awareness and widespread screening programs. It summarizes current knowledge on the clinicopathological subtypes of BC, assessment of hormonal receptor status, and the role of immunohistochemical and molecular-genetic testing in treatment decisions. Diagnostic imaging techniques (mammography, tomosynthesis, ultrasound, magnetic resonance imaging) and their diagnostic value are discussed, along with clinical examination algorithms. Special emphasis is placed on modern technologies, especially artificial intelligence, in automated image analysis for mammography and ultrasound. The integration of deep learning with medical imaging data improves diagnostic accuracy, allows detection of pathological changes at the preclinical stage, and reduces diagnostic errors. A key focus is the multidisciplinary approach to managing BC patients, which involves coordination among healthcare providers, adherence to current clinical protocols, and the use of genomic assays (such as Oncotype DX, MammaPrint), with personalized treatment plans. The lecture underlines the necessity of ongoing professional development for healthcare workers at all levels through postgraduate education, aiming to establish standardized algorithms for early BC detection. Overall, the lecture aims to provide students with a thorough understanding of modern principles in breast cancer diagnostics and strategies for enhancing their effectiveness in Ukraine, considering global trends, national challenges, and innovative approaches. Keywords: breast cancer symptoms, diagnostic algorithm, artificial intelligence in diagnosis.

  • Open Access

    Exploring New Frontiers: Alternative Breast Cancer Treatments Through Glycocalyx Research

    by Ielizaveta Gorodetska, Anastasiia Samusieva, Tetiana Lahuta, Olga Ponomarova, Oleg Socha, Iryna Kozeretska

    Breast cancer (BC) treatment is developing toward more precise and personalized care through the approval of different comprehensive approaches. Clinical practice emphasizes significant patient‐to‐patient variability in treatment response among patients, even those with similar clinical and biological profiles. Recent studies have demonstrated that the glycocalyx is an essential organelle that plays an important role in many cellular processes and can be a promising target for treatment. The glycocalyx of cancer cells is a key component influencing the interaction between the tumor and the immune system. Glycan modifications attached to glycoproteins and glycolipids are a common characteristic of the transition to malignancy. We review how the specific structure and function of the glycocalyx are regulated at the molecular level, contribute to immune evasion, and can be overcome by using both traditional drugs and combination therapies, as well as drugs not previously used in standard cancer treatments, to address treatment resistance associated with glycocalyx alterations. Trial Registration: ClinicalTrials.gov identifier: NCT00770354, NCT00925548, NCT01731587, NCT00088413, NCT00179309, NCT00986609, NCT05812326, NCT04020575, NCT05239143, NCT01279603, and NCT03562637


  • Open Access

    Organization of Palliative Care Provision in the Palliative Care Department During War Time

    by Raisa Moiseenko, Oleksii Kalachov, Prokip Gordiichuk, Andrii Kondratenko, Anna Konysheva, Mykola Gordiichuk, Anastasiia Samusieva, Раїса Моісеєнко, Прокіп Гордійчук, Микола Гордійчук, et al.

    The city of Kyiv is characterized by a high level (258.6 cases per 100,000 population) of cancer incidence and mortality. The objective: to determine the problem and prospects of providing inpatient oncology care based on the experience of the department of the Kyiv City Clinical Oncology Center (KCCOC). Materials and methods. A retrospective analysis of the work of the palliative care department of communal non-commercial enterprise “KCCOC” for 2001–2023 was carried out. The center includes a 25-bed hospital and mobile palliative care teams. A multidisciplinary approach was the basis of providing palliative care to an incurable cancer patient. Results. During this period 9,164 cancer patients in the terminal stage with high mortality rate (81.04%) received inpatient care. The average duration of stay in the hospital was 17.7 bed-days. Approximately 6% of patients readmit to the department, some of them – 3-4 times. Approximately 94% of hospitalized patients had a pain syndrome, 86% of patients received opioid analgesia. During this period, mobile palliative care teams registered and served 3,124 cancer patients, among whom 62% of patients were transferred after inpatient treatment, more than 5,700 primary visits were made. The clinical route of the palliative patient was developed and improved, which made it possible to optimize palliative care for a seriously ill oncological patient. The peculiarities of providing palliative care to incurable oncological patients in the conditions of martial law have been determined. Conclusions. Comprehensive palliative care should be a unified system of mobile and stationary care, which will make possible to control the somatic condition of the palliative patient, correct the symptoms of the disease, provide long-term support to the patient at home, which is economically feasible, allows to provide care to a larger number of patients and hospitalize in time if it is necessary. The creation of an extensive system of mobile palliative care is promising in improvement of palliative care for oncology patients (it will reduce the burden on general somatic hospitals and inpatient palliative departments), as well as qualitatively improve the provision of palliative care to patients in the primary care network.

  • Open Access

    Planning and use of oncoplastic surgery for breast cancer

    by A.A. Samusieva, R.V. Liubota, V.V. Zaichuk, О.в. Пономарьова, I.I. Liubota

    На сьогодні зростає популярність органозберігальних операцій на грудних залозах серед жінок із ранніми стадіями раку грудної залози. Крім того, ці операції не відрізняються онкологічною радикальністю та не демонструють різниці стосовно показників виживання порівняно з мастектомією, однак їхні косметичні та психологічні переваги є суттєвими. У пошуках балансу між ризиком місцевого рецидиву та косметичними результатами при хірургічних втручаннях при раку грудної залози були запроваджені нові хірургічні варіанти – поєднання органозберігальної операції з методами пластичної хірургії, так звані онкопластичні операції. За останнє десятиріччя широкого розвитку у хірургічному лікуванні раку грудної залози отримала саме онкопластична хірургія. При онкопластичних операціях на грудній залозі пухлини верхньовнутрішнього квадранта є особливо проблемними і вимагають більшої уваги хірурга. У цьому випадку розмір і розташування пухлини – два важливі фактори для післяопераційного косметичного результату. У статті представлено модифіковану техніку з використанням дермогландулярного ротаційного клаптя, яка може бути застосована для відносно великих пухлин внутрішнього квадранта грудної залози без хірургічного втручання на контралатеральній грудній залозі для симетризації. Застосування цієї методики дозволяє зберегти грудну залозу при більших розмірах пухлини без шкоди для зовнішнього вигляду грудних залоз. Важливим елементом органозберігального хірургічного лікування є передопераційне оцінювання клініко-біологічних особливостей та морфологічних аспектів пухлини, що дозволяє хірургу прийняти рішення про можливість консервативного лікування та вибрати найбільш ефективну онкопластичну хірургічну техніку. Онкопластичні операції можуть покращити косметичний ефект та задоволеність пацієнтів без шкоди для онкологічних результатів, що підтверджує клінічну корисність цього підходу до хірургічного лікування пацієнтів з раком грудної залози. У статті наведено клінічні випадки – пацієнтки 46 років із раком лівої грудної залози (стадія І cT1N0M0 pT1N0M0) та хворої 42 років із раком правої грудної залози (стадія І cT1NxM0 pT1N0M0), у лікуванні яких застосовували описану методику.

  • Contribution of BRCA1 5382insC mutation to triplene-gative and luminal types of breast cancer in Ukraine

    by Anastasiia Samusieva, Svitlana Serga, Sergiy Klymenko, Lyudmila Rybchenko, Bohdana Klimuk, Liubov Zakhartseva, Natalia Gorovenko, Olga Lobanova, Zoia Rossokha, Liliia Fishchuk, et al.

    Purpose The gene BRCA1 plays a key role in DNA repair in breast and ovarian cell lines and this is considered one of target tumor suppressor genes in same line of cancers. The 5382insC mutation is among the most frequently detected in patients (Eastern Europe) with triple-negative breast cancer (TNBC). In Ukraine, there is not enough awareness of necessity to test patients with TNBC for BRCA1 mutations. That is why this group of patients is not well-studied, even through is known the mutation may affect the course of disease. Methods The biological samples of 408 female patients were analyzed of the 5382insC mutation in BRCA1. We compared the frequency of the 5382insC mutation in BRCA1 gene observed in Ukraine with known frequencies in other countries. Results For patients with TNBC, BRCA1 mutations frequency was 11.3%, while in patients with luminal types of breast cancers, the frequency was 2.8%. Prevalence of 5382insC among TNBC patients reported in this study was not different from those in Tunisia, Poland, Russia, and Bulgaria, but was higher than in Australia and Germany. Conclusion The BRCA1 c.5382 mutation rate was recorded for the first time for TNBC patients in a Ukrainian population. The results presented in this study underscore the importance of this genetic testing of mutations in patients with TNBC. Our study supports BRCA1/2 genetic testing for all women diagnosed with TNBC, regardless of the age of onset or family history of cancer and not only for women diagnosed with TNBC at <60y.o., as guidelines recommend.


  • Open Access

    Протипухлинна хіміотерапія: можливі ризики, помилки при проведенні й шляхи їх профілактики

    by A.A. Samusieva, A.S. Zotov

    Хіміотерапія є важливим і невід’ємним методом лікування в онкології, помилки при призначенні й проведенні якої є серйозною проблемою. У статті розглянуто основні організаційні, технічні й адміністративні фактори, від яких залежить частота й характер цих помилок. Окреслені можливі шляхи профілактики порушень стандартів і правил проведення протипухлинного медикаментозного лікування.

  • Open Access

    CLINICAL CASE GRANULAR CELL TUMOR OF BREAST

    by Array С. Зотов, A. A. Samusieva, M. V. Dyatel

    В статье описывается случай диагностики редкой стромальной опухоли молочной железы, которая на этапах диагностики трактовалась как подозрение на карциному. Только иммуногистохимическое исследование помогло окончательно установить природу и доброкачественный характер новообразования.